EP3463457
PD-1 bæling með nívólúmabi í Hodgkinseitlaæxli sem er erfitt viðureignar
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
1.6.2017EP published:
28.6.2023EP application number:
17730627.1
EP translation filed:
12.9.2023Grant published:
15.10.2023EPO information:
European Patent Register
Max expiry date:
31.5.2037Expiry date:
31.5.2026Next due date:
30.6.2026
Title in English:
PD-1 BLOCKADE WITH NIVOLUMAB IN REFRACTORY HODGKIN'S LYMPHOMALanguage of the patent:
English
Timeline
Today
1.6.2017EP application
28.6.2023EP Publication
12.9.2023Translation submitted
15.10.2023Registration published
31.5.2026Expires
Owner
Name:
Bristol-Myers Squibb CompanyAddress:
Route 206 and Province Line Road, Princeton, NJ 08543, US
Inventor
Name:
FARSACI, BenedettoAddress:
Princeton New Jersey 08543, US
Agent
Name:
G.H. Sigurgeirsson ehf.Address:
Borgartúni 26, 105, Reykjavík,
Priority
Number:
201662344880 PDate:
2.6.2016Country:
US
Classification
Categories:
A61K 39/395, C07K 16/28, A61K 39/00
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 7.5.2024
Expires: 31.5.2025
Payer: Árnason Faktor ehf.
Number: 9
Paid: 16.5.2025
Expires: 31.5.2026
Payer: Árnason Faktor ehf.